drugset
drugset / Trial / NCT00550212

Study Evaluating Oral Administrations of HKI-272 in Healthy Male Subjects

NCT00550212 ↗

Phase 1 Completed 6 enrolled Puma Biotechnology, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the mass balance and metabolic distribution of C14-labeled HKI-272 in healthy male subjects.

Timeline

Start
2008-03
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Neratinib Small molecule 240 mg Oral

Indications

No indication recorded.